EP1063891A4 - Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes - Google Patents
Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodesInfo
- Publication number
- EP1063891A4 EP1063891A4 EP99912710A EP99912710A EP1063891A4 EP 1063891 A4 EP1063891 A4 EP 1063891A4 EP 99912710 A EP99912710 A EP 99912710A EP 99912710 A EP99912710 A EP 99912710A EP 1063891 A4 EP1063891 A4 EP 1063891A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- antigen
- methods
- presenting cells
- compositions produced
- enhanced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000030741 antigen processing and presentation Effects 0.000 title 1
- 210000000612 antigen-presenting cell Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7888098P | 1998-03-20 | 1998-03-20 | |
US78880P | 1998-03-20 | ||
PCT/US1999/006031 WO1999047102A2 (fr) | 1998-03-20 | 1999-03-19 | Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1063891A2 EP1063891A2 (fr) | 2001-01-03 |
EP1063891A4 true EP1063891A4 (fr) | 2002-10-23 |
Family
ID=22146768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99912710A Withdrawn EP1063891A4 (fr) | 1998-03-20 | 1999-03-19 | Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1063891A4 (fr) |
JP (1) | JP2002506622A (fr) |
AU (1) | AU755156B2 (fr) |
CA (1) | CA2322750A1 (fr) |
WO (1) | WO1999047102A2 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005084387A2 (fr) * | 2004-03-02 | 2005-09-15 | Tsuneya Ohno | Procedes et compositions ayant trait a des vaccins de cellules hybrides de traitement et prevention du cancer |
US9085807B2 (en) | 2004-09-14 | 2015-07-21 | Argos Therapeutics, Inc. | Strain-independent amplification of pathogens and vaccines thereto |
WO2009008713A1 (fr) * | 2007-07-09 | 2009-01-15 | Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Ce | Inhibiteurs de tap à partir d'herpèsvirus 1 de primate d'europe et leur utilisation |
CN104761644A (zh) * | 2014-01-03 | 2015-07-08 | 百奇生物科技(苏州)有限公司 | 大肠杆菌表达的融合蛋白mbp-mart-1及其制备和应用 |
US20170363629A1 (en) * | 2014-11-05 | 2017-12-21 | Board Of Regents, The University Of Texas System | Biomarkers and targets for cancer immunotherapy |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995015384A1 (fr) * | 1993-11-30 | 1995-06-08 | Johnson David C | Proteine virale vecteur, sequence nucleotidique codant pour cette proteine et procede permettant d'inhiber la reconnaissance immuniataire |
WO1997007128A1 (fr) * | 1995-08-21 | 1997-02-27 | Duke University | Procede pour accroitre la densite d'un antigene sur une cellule presentant un antigene |
US5674486A (en) * | 1991-06-25 | 1997-10-07 | San Diego Regional Cancer Center | Cancer immunotherapy with carrier cells |
-
1999
- 1999-03-19 CA CA002322750A patent/CA2322750A1/fr not_active Abandoned
- 1999-03-19 AU AU31023/99A patent/AU755156B2/en not_active Ceased
- 1999-03-19 EP EP99912710A patent/EP1063891A4/fr not_active Withdrawn
- 1999-03-19 JP JP2000536343A patent/JP2002506622A/ja not_active Withdrawn
- 1999-03-19 WO PCT/US1999/006031 patent/WO1999047102A2/fr active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674486A (en) * | 1991-06-25 | 1997-10-07 | San Diego Regional Cancer Center | Cancer immunotherapy with carrier cells |
WO1995015384A1 (fr) * | 1993-11-30 | 1995-06-08 | Johnson David C | Proteine virale vecteur, sequence nucleotidique codant pour cette proteine et procede permettant d'inhiber la reconnaissance immuniataire |
WO1997007128A1 (fr) * | 1995-08-21 | 1997-02-27 | Duke University | Procede pour accroitre la densite d'un antigene sur une cellule presentant un antigene |
Non-Patent Citations (5)
Title |
---|
BANKS THERESA A ET AL: "Vaccination with the immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) induces virus-specific lymphoproliferation, but fails to protect against lethal challenge.", VIROLOGY, vol. 200, no. 1, 1994, pages 236 - 245, XP002210423, ISSN: 0042-6822 * |
JUGOVIC PIETER ET AL: "Inhibition of major histocompatibility complex class I antigen presentation in pig and primate cells by herpes simplex virus type 1 and 2 ICP47.", JOURNAL OF VIROLOGY, vol. 72, no. 6, June 1998 (1998-06-01), pages 5076 - 5084, XP002210422, ISSN: 0022-538X * |
LIU T ET AL: "TAP peptide transporter-independent presentation of heat-killed Sendai virus antigen on MHC class I molecules by splenic antigen-presenting cells.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 DEC 1997, vol. 159, no. 11, 1 December 1997 (1997-12-01), pages 5364 - 5371, XP002210421, ISSN: 0022-1767 * |
NEUMANN LARS ET AL: "The active domain of the herpes simplex virus protein ICP47: A potent inhibitor of the transporter associated with antigen processing (TAP).", JOURNAL OF MOLECULAR BIOLOGY, vol. 272, no. 4, 1997, pages 484 - 492, XP002210420, ISSN: 0022-2836 * |
WONG C ET AL: "INDUCTION OF PRIMARY, HUMAN ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTES IN VITRO USING DENDRITIC CELLS PULSED WITH PEPTIDES", JOURNAL OF IMMUNOTHERAPY, RAVEN PRESS, NEW YORK, NY, US, vol. 21, no. 1, 15 January 1998 (1998-01-15), pages 32 - 40, XP002919848, ISSN: 1053-8550 * |
Also Published As
Publication number | Publication date |
---|---|
EP1063891A2 (fr) | 2001-01-03 |
AU755156B2 (en) | 2002-12-05 |
WO1999047102A3 (fr) | 1999-10-21 |
CA2322750A1 (fr) | 1999-09-23 |
AU3102399A (en) | 1999-10-11 |
WO1999047102A2 (fr) | 1999-09-23 |
JP2002506622A (ja) | 2002-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0016438D0 (en) | Methods and compositions for desensitisation | |
AU2001280189A1 (en) | Air refining device and ion generator used for the device | |
AU7342098A (en) | Presentation device | |
AU7158398A (en) | Use of lentiviral vectors for antigen presentation in dendritic cells | |
AU6505299A (en) | Methods for generating antigen-reactive t cells (in vitro) | |
AU2349399A (en) | R-lansoprazole compositions and methods | |
AU7116798A (en) | Silicon greases and methods for their production | |
AU2410999A (en) | Presentation device | |
AU4642600A (en) | Methods and compositions for use in potentiating antigen presentation by antigenpresenting cells | |
AU2664797A (en) | Wnt receptor compositions and methods | |
EP1165773A4 (fr) | Plate-forme perfectionnee de presentation d'antigenes | |
AU3802199A (en) | Presentation device | |
EP1073333A4 (fr) | Compositions a base de s-rabeprazole et procedes | |
EP1075184A4 (fr) | Compositions et procedes de vaccination active | |
AU7134598A (en) | Plant propagation compositions and methods | |
EP1063891A4 (fr) | Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes | |
AU7308200A (en) | Novel hev antigenic peptide and methods | |
GB9705744D0 (en) | Methods for selecting cells and their uses | |
AU7358098A (en) | Radioisotope concentrator methods and compositions | |
AU4706199A (en) | Compositions and methods for inducing apoptosis in e6-expressing cells | |
AUPO982097A0 (en) | Methods and compositions for use therein | |
AU2001261534A1 (en) | The meca-79 antigen and related methods | |
AU7442296A (en) | Generating d-peptides: methods and compositions | |
AU8513698A (en) | Methods and compositions for designing vaccines | |
EP1071325A4 (fr) | Compositions et methodes de vaccination specifique de l'antigene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000920 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20020911 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20021219 |